Cancer: Cancer (unspecified)

  Manage Alerts
Collapse Summary Pipeline Information
 Disease Dashboard for Cancer (unspecified)
18 - All unpartnered indications 7 - All partnered indications 6 - All unpartnered indications 2 - All partnered indications 18 - All unpartnered indications 14 - All partnered indications 143 - All unpartnered indications 53 - All partnered indications 425 - All unpartnered indications 62 - All partnered indications
223 212 23 20 17
10 - Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) 10 - Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) 13 - c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) 16 - Phosphoinositide 3-kinase (PI3K) 23 - Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Preclinical = Research, IND, Phase 0, Pilot;
Phase I = Phase I, Phase I/II;
Phase II = Phase II, Phase II/III;
Phase III = Pivotal, Phase III, Registration;
Market = Phase IV, Approved not yet marketed, Marketed
 Pipeline Summary for Cancer (unspecified)
 Pipeline Details for Cancer (unspecified)
Collapse Summary Deals Information
 Deals Summary for Cancer (unspecified)
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1584

$476,444.3M

$292,820.0M

$80,838.3M


 Deals Details for Cancer (unspecified)
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone